PTC Therapeutics

PTCT

Market cap $6.9B

Emma Reeve recently exercised some PTC Therapeutics stock options and sold the shares immediately. Reeve is an independent board director at PTC Therapeutics.

NEW YORK , Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:  S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (NYSE: IPG) in the S&P 500, and PTC Therapeutics Inc. (NASD: PTCT) will replace Sandisk in the S&P SmallCap 600 effective prior to the opening of trading on Friday, November 28. S&P 500 constituent Omnicom Group Inc. (NYSE: OMC) is acquiring The Interpublic Group of Companies in a deal expected to close soon, pending final conditions.

Event to take place on Dec. 2, 2025 in New York City WARREN, N.J. , Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its pipeline on Dec. 2, 2025, at 9:30 a.m.

New York City-based Armistice Capital sold 1,458,192 shares of PTC Therapeutics for an estimated $30.2 million in the third quarter. At quarter-end, Armistice reporting holding a total of nearly 3.3 million PTC Therapeutics shares valued at $201.1 million.

PTC Therapeutics, Inc. ( PTCT ) UBS Global Healthcare Conference 2025 November 11, 2025 3:30 PM EST Company Participants Matthew Klein - CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.

PTC Therapeutics, Inc. ( PTCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Ellen Cavaleri Matthew Klein - CEO & Director Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tazeen Ahmad - BofA Securities, Research Division Brian Abrahams - RBC Capital Markets, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Judah Frommer - Morgan Stanley, Research Division Yuxi Dong - Jefferies LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Huidong Wang - Barclays Bank PLC, Research Division Samantha Corwin - William Blair & Company L.L.C., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Luke Herrmann - Robert W.

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

PTC Therapeutics (PTCT) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of a loss of $1.19 per share. This compares to a loss of $1.39 per share a year ago.

– Initiated US and EU launch of Sephience™ (sepiapterin) –  – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – – Robust Q3 performance with total revenue of $211M – – Full-year 2025 revenue guidance narrowed to $750 - $800M – WARREN, N.J. , Nov. 4, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025.

WARREN, N.J. , Oct. 31, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: UBS Global Healthcare Conference 2025 Tuesday, Nov. 11 at 3:30 p.m.